Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
record last updated June 5, 2025
Saxenda (active ingredient: liraglutide) subcutaneous injection Initial FDA Approval: 2014 (liraglutide approved in 2010) Side Effect Update Date: May 28, 2025 Medication Description: For chronic weight management Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
Across the broader GLP-1 class, approved indications include type 2 diabetes for most compounds, chronic weight management for products like Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for several products, and obstructive sleep apnea in adults with obesity for Zepbound as of 2024
Acylcarnitine profiles reflect metabolic vulnerability for necrotizing enterocolitis in newborns born premature
US$ 21.54
US$ 23.47
US$ 25.30
US$ 27.47
US$ 24.41
US$ 24.29
US$ 24.10
US$ 24.04
US$ 29.89
